RxDoctor Payments Data

Brian Wolff, MD

Neurology · Naples, FLNPI 1225089048

Payments from drug & device makers

$1,253in general payments, 2019–2025

Across 22 payments — averaging $56.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$219
  • UCB, Inc.$167
  • Livanova USA, Inc.$141
  • Biohaven Pharmaceuticals, Inc.$133
  • Sanofi$121
  • Greenwich Biosciences, Inc.$121
  • plus $353 from 5 others

What the payments were for

  • Food & beverage$1,24599%
  • Education$81%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,253 in reported general payments places this provider in the 40th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$129,366
Medicare patients
382
Services billed
931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate100$195,262
AustedoDeutetrabenazine11$164,891
Emgality PenGalcanezumab-Gnlm42$35,248
UbrelvyUbrogepant24$29,314
Aimovig AutoinjectorErenumab-Aooe11$14,037
Rasagiline Mesylate56$8,209
Carbidopa-LevodopaCarbidopa/Levodopa177$6,411
Gabapentin124$4,101
Tegretol XrCarbamazepine12$3,451
Entacapone13$2,080
RivastigmineRivastigmine Tartrate23$1,935
Mirtazapine28$1,749
AmantadineAmantadine Hcl27$1,562
Midodrine Hcl16$1,354
Carbidopa-Levodopa ErCarbidopa/Levodopa20$1,308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$219$164,89111 claims
AbbVieUbrelvy$119$29,31424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,434 neurology providers in Florida.

Other neurology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →